Lymph node status and tumour size are anatomic prognostic factors that can easily be used to identify patients at highest risk of recurrence, i.e. patients who will most likely experience the highest absolute benefit of extended aromatase inhibition.3 Here, CYP19A1 is linked to neoplasm.